These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 26810187)

  • 21. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
    Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
    Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
    Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
    Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
    Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
    Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
    Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast.
    Tsuchiya B; Iwaya K; Kohno N; Kawate T; Akahoshi T; Matsubara O; Mukai K
    Histopathology; 2012 Jul; 61(1):69-77. PubMed ID: 22385318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis.
    Sanpaolo P; Barbieri V; Pedicini P; Fusco V
    Med Oncol; 2012 Jun; 29(2):459-65. PubMed ID: 21359639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.